By Steve Edelson
Staff writer

For the low-margin diagnostics industry, pharmacogenomics offers the ability to increase the impact of diagnostics on clinical decision making, and consequently make the field more attractive and profitable. As a result, major diagnostics players are adding pharmacogenomics capabilities to their platforms as highlighted by last week's deal between Millennium Predictive Medicine Inc. and Becton Dickinson Co. What remains to be seen, however, is when products will appear on the market and what prices they will command.